-
EP3854806
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3854806
| EP3854806 - NOVEL INTERLEUKIN 2 AND USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 25.06.2021 Database last updated on 15.06.2024 | |
| Former | The international publication has been made Status updated on 28.03.2020 | Most recent event Tooltip | 08.09.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Innovent Biologics (Suzhou) Co., Ltd. 168 Dongping Street Suzhou Industrial Park Suzhou, Jiangsu 215123 / CN | [2021/30] | Inventor(s) | 01 /
KANG, Lishan 168 Dongping Street Suzhou Industrial Park Suzhou, Jiangsu 215123 / CN | 02 /
GU, Chunyin 168 Dongping Street Suzhou Industrial Park Suzhou, Jiangsu 215123 / CN | 03 /
FU, Fenggen 168 Dongping Street Suzhou Industrial Park Suzhou, Jiangsu 215123 / CN | 04 /
ZHOU, Shuaixiang 168 Dongping Street Suzhou Industrial Park Suzhou, Jiangsu 215123 / CN | 05 /
SHI, Xinzhen 168 Dongping Street Suzhou Industrial Park Suzhou, Jiangsu 215123 / CN | 06 /
LIU, Junjian 168 Dongping Street Suzhou Industrial Park Suzhou, Jiangsu 215123 / CN | [2021/30] | Representative(s) | Sagittarius IP Marlow International Parkway Marlow SL7 1YL / GB | [N/P] |
| Former [2021/30] | Teuten, Andrew John Sagittarius IP Marlow International Parkway Marlow SL7 1YL / GB | Application number, filing date | 19862253.2 | 20.09.2019 | [2021/30] | WO2019CN107055 | Priority number, date | CN201811108649 | 21.09.2018 Original published format: CN201811108649 | [2021/30] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020057646 | Date: | 26.03.2020 | Language: | ZH | [2020/13] | Type: | A1 Application with search report | No.: | EP3854806 | Date: | 28.07.2021 | Language: | EN | [2021/30] | Search report(s) | International search report - published on: | CN | 26.03.2020 | (Supplementary) European search report - dispatched on: | EP | 24.08.2022 | Classification | IPC: | C07K14/55, C12N15/63, C12N15/26, A61P35/00, A61P31/12, A61K39/39, A61K38/20, A61K47/68, A61K38/00, C12N15/81 | [2022/25] | CPC: |
C12N15/81 (EP);
C07K14/55 (EP,US);
A61K47/68 (EP);
A61K47/6843 (US);
A61K47/6845 (US);
A61K47/6853 (US);
A61K47/6865 (US);
A61K47/6871 (US);
A61P31/12 (EP);
A61P35/00 (EP);
C07K16/18 (US);
C07K16/248 (US);
C07K16/3007 (US);
C07K16/3053 (US);
C07K16/40 (US);
C12P21/02 (US);
A61K38/00 (EP,US);
C07K2317/55 (US);
|
| Former IPC [2021/30] | C07K14/55, C12N15/63, C12N15/26, A61P35/00, A61P31/12, A61K39/39, A61K38/20 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/30] | Title | German: | NEUARTIGES INTERLEUKIN 2 UND SEINE VERWENDUNG | [2021/30] | English: | NOVEL INTERLEUKIN 2 AND USE THEREOF | [2021/30] | French: | NOUVELLE INTERLEUKINE 2 ET UTILISATION ASSOCIÉE | [2021/30] | Entry into regional phase | 25.11.2020 | Translation filed | 25.11.2020 | National basic fee paid | 25.11.2020 | Search fee paid | 25.11.2020 | Designation fee(s) paid | 25.11.2020 | Examination fee paid | Examination procedure | 25.11.2020 | Examination requested [2021/30] | 23.02.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 01.09.2021 | Renewal fee patent year 03 | 07.07.2022 | Renewal fee patent year 04 | 08.09.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO2015110002 (LIU GENTAO [CN], et al) [I] 1,7-16 * claims 1, 5, 6 *; | [I]CA2946398 (UNIV LELAND STANFORD JUNIOR [US], et al) [I] 1,7-16 * claims 1, 2a-10 *; | [XP]WO2019028419 (SYNTHORX INC [US]) [XP] 1,5,7-16 * claims 1, 4, 64-69 ** paragraphs [0078] - [0082] - [ 276] - [0291] - [ 316] - [0324] *; | [E]WO2020020783 (BIONTECH RNA PHARMACEUTICALS GMBH [DE], et al) [E] 1,5,7-16 * page 3, lines 17-21 * * page 9, lines 12-30 * * page 13, lines 1-32 * * page 38, line 28 - page 44, line 28 * * page 63, line 1 - page 69, line 28 * * examples 1,3; claims 24, 25 *; | [I] - ARON M. LEVIN ET AL, "Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’", NATURE, (20120325), vol. 484, no. 7395, doi:10.1038/nature10975, ISSN 0028-0836, pages 529 - 533, XP055214333 [I] 1,7-16 * page 2, paragraphs 3,4 * * figure 1c * * supplementary figure 3 * DOI: http://dx.doi.org/10.1038/nature10975 |